---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000051"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T01:21:20.901558+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allogene reports Q1 net loss $98.7M, cash $514M; clinical progress in ALLO-501A and ALLO-316

## Summary
- Net loss $98.7M ($0.68/share); R&D $80.2M, G&A $18.9M; cash $514M as of March 31, 2023.
- Phase 2 ALPHA2 trial enrollment ongoing for ALLO-501A in R/R large B cell lymphoma; expects enrollment completion 1H 2024.
- Initiated EXPAND trial to support licensure of ALLO-647; randomized ~70 patients to FCA90 vs FC alone before ALLO-501A.
- Interim Phase 1 data on ALLO-316 in RCC: 3 of 10 CD70+ patients achieved partial response; disease control rate 100% in CD70+ subset.
- Appointed Timothy Moore as Chief Technical Officer; fiscal 2023 guidance: cash burn ~$230M, GAAP OpEx ~$340M, runway into Q2 2025.

## SEC filing metadata
- accession: 0001737287-23-000051
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000051/0001737287-23-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000051/allo-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000051
- JSON: https://secwatch.observer/filing/0001737287-23-000051.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000051.txt

## Key facts
- Earnings Releases
  Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 3, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000051/0001737287-23-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.